3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
31
Colorectal Neoplasms
18
Carcinoma, Hepatocellular
18
Stomach Neoplasms
12
Esophageal Squamous Cell Carcinoma
12
Squamous Cell Carcinoma of Head and Neck
9
Neoplasm Metastasis
9
Advanced Solid Tumor
9
Lung Neoplasms
7
Head and Neck Neoplasms
7
Rectal Neoplasms
5
Esophageal Neoplasms
5
Small Cell Lung Carcinoma
4
Neoplasms
4
Nasopharyngeal Carcinoma
4
Melanoma
4
Solid Tumor
3
Lymphoma, Follicular
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Biliary Tract Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma
2
Hodgkin Disease
2
Interventions
lutetium Lu 177 dotatate
21
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
Capecitabine
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
tislelizumab
×
1 year
×
Clear all
No trials found.